Omega Healthcare Investors (OHI)

NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-10-23

$46.23-0.15%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Omega Healthcare Investors’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	278.78M
EPS	—	0.481
FY 2026 · Annual
Revenue	—	1.09B
EPS	—	2.653
Adjusted FFO per share	$3.22–$3.26non-GAAP	—
FY 2027 · Annual
Revenue	—	1.18B
EPS	—	2.021

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain dividend per share at $0.67	Omega Healthcare Investors keeps paying a steady dividend of $0.67 per share.	Intact	dividend per share falls below $0.67 next 4 quarters	Dividend per share: $0.67 per share FY2026-Q2; GAAP. Published target: >= $0.67 per share. Target period is not explicitly aligned with this observation. Source published Jul 30, 20260.67 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5bbdeb5d-ba5d-43ce-8d8a-f3d7266a09d7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. The quarterly dividend per share was maintained at $0.67 from 2025-Q3 through 2026-Q1 and increased by $0.01 to $0.68 in 2026-Q2. This reflects management's consistent commitment to dividend growth, delivering on the stated priority. Delivery assessment Oct 24, 2026
Achieve EPS near $3.22 for FY 2026	A supporting condition in Omega Healthcare Investors's published investment case. The stated target is EPS between $3.19 and $3.25.	Intact	EPS guidance falls below $3.19 for FY 2026	Diluted EPS: $1.19 per share FY2026-Q2; GAAP. Published target: EPS between $3.19 and $3.25. Target period is not explicitly aligned with this observation. Source published Jul 30, 20261.19 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5bbdeb5d-ba5d-43ce-8d8a-f3d7266a09d7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Net income improves to positive $151 million quarterly	Net income improved strongly to $151 million from a prior loss.	Intact	net income falls below zero next 4 quarters	Net income: $362.823M FY2026-Q2; GAAP. Published target: >= $150 million quarterly. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026362,823,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5bbdeb5d-ba5d-43ce-8d8a-f3d7266a09d7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Increase revenue to at least $323 million quarterly	A primary condition in Omega Healthcare Investors's published investment case. The stated target is >= $323 million quarterly.	Intact	quarterly revenue falls below $319 million	Revenue: $328.246M FY2026-Q2; GAAP. Published target: >= $323 million quarterly. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026328,246,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5bbdeb5d-ba5d-43ce-8d8a-f3d7266a09d7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$2.03 → Unavailable · observed estimates

FY2027 revenueUnavailable

$1.16B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.03	$1,155,032,990	5 / 9
2026-07-25	$2.03	$1,156,256,660	5 / 9
2026-07-26	$2.03	$1,156,256,660	5 / 9
2026-07-27	$2.03	$1,156,256,660	5 / 9
2026-07-28	$2.03	$1,156,256,660	5 / 9
2026-07-29	$2.03	$1,156,256,660	5 / 9
2026-07-30	$2.03	$1,156,256,660	5 / 9
2026-07-31	$2.01	$1,154,260,434	5 / 6
2026-08-01	$2.01	$1,154,260,434	5 / 6
2026-08-02	$2.04	$1,162,148,870	5 / 8
2026-08-03	$2.02	$1,135,303,378	5 / 6
2026-08-04	$2.02	$1,135,303,378	5 / 6
2026-08-05	$2.02	$1,135,303,378	5 / 6
2026-08-06	$2.04	$1,162,148,870	5 / 8
2026-08-07	$2.02	$1,135,303,378	5 / 6
2026-08-08	$2.04	$1,161,114,240	5 / 8
2026-08-09	$2.04	$1,161,114,240	5 / 8
2026-08-10	$2.04	$1,161,114,240	5 / 8
2026-08-12	$2.04	$1,161,114,240	5 / 8
2026-08-13	$2.02	$1,135,303,378	5 / 6
2026-08-14	$2.02	$1,135,303,378	5 / 6
2026-08-15	$2.02	$1,135,303,378	5 / 6
2026-08-16	$2.02	$1,135,303,378	5 / 6
2026-08-17	$2.02	$1,135,303,378	5 / 6
2026-08-18	$2.02	$1,135,303,378	5 / 6
2026-08-19	$2.02	$1,135,303,378	5 / 6
2026-08-20	$2.03	$1,140,506,749	6 / 7
2026-08-21	$2.04	$1,140,506,749	6 / 6
2026-08-22	$2.01	$1,140,506,749	6 / 6
2026-08-23	$2.01	$1,140,506,749	6 / 6
2026-08-24	$2.01	$1,140,506,749	6 / 5
2026-08-25	$2.01	$1,140,506,749	6 / 5
2026-08-26	$2.01	$1,140,506,749	6 / 5
2026-08-27	$2.01	$1,140,506,749	6 / 5
2026-08-28	$2.01	$1,140,506,749	6 / 5
2026-08-29	$2.02	$1,142,594,449	6 / 5
2026-08-30	$2.02	$1,142,594,449	6 / 5
2026-08-31	$2.02	$1,142,594,449	6 / 5
2026-09-01	$2.02	$1,142,594,449	6 / 5
2026-09-02	$2.02	$1,142,594,449	6 / 5
2026-09-03	$2.00	$1,139,836,437	6 / 5
2026-09-04	$2.00	$1,139,836,437	5 / 5
2026-09-05	$2.00	$1,139,836,437	5 / 5
2026-09-06	$2.00	$1,139,836,437	5 / 5
2026-09-07	$2.00	$1,139,836,437	5 / 5
2026-09-08	$2.00	$1,139,836,437	5 / 5
2026-09-09	$2.00	$1,139,836,437	5 / 5
2026-09-10	$2.00	$1,139,836,437	5 / 5
2026-09-11	$2.00	$1,139,836,437	5 / 5
2026-09-12	$2.00	$1,141,776,437	5 / 5
2026-09-13	$2.00	$1,141,776,437	5 / 5
2026-09-14	$2.00	$1,141,776,437	5 / 5
2026-09-15	$2.00	$1,141,776,437	5 / 5
2026-09-16	$2.00	$1,141,776,437	5 / 5
2026-09-17	$2.00	$1,141,776,437	5 / 5
2026-09-18	$2.00	$1,141,776,437	5 / 5
2026-09-19	$2.00	$1,141,776,437	5 / 5
2026-09-20	$2.00	$1,141,746,822	5 / 5
2026-09-21	$2.00	$1,141,746,822	5 / 5
2026-09-22	$2.00	$1,141,746,822	5 / 5
2026-09-23	$2.00	$1,141,746,822	5 / 5
2026-09-24	$2.00	$1,141,746,822	5 / 5
2026-09-25	$2.00	$1,141,746,822	5 / 5
2026-09-26	$2.00	$1,141,746,822	5 / 5
2026-09-27	$2.00	$1,141,746,822	5 / 5
2026-09-28	$2.00	$1,141,746,822	5 / 5
2026-09-29	$2.00	$1,141,746,822	5 / 5
2026-09-30	$2.00	$1,141,746,822	5 / 5
2026-10-01	$2.00	$1,141,746,822	5 / 5
2026-10-02	$2.00	$1,141,746,822	5 / 5
2026-10-03	$2.00	$1,141,746,822	5 / 5
2026-10-04	$2.00	$1,141,746,822	5 / 5
2026-10-05	$2.00	$1,141,746,822	5 / 5
2026-10-06	$2.00	$1,141,746,822	5 / 5
2026-10-07	$2.00	$1,167,375,660	5 / 5
2026-10-08	$2.00	$1,167,375,660	5 / 5
2026-10-09	$2.00	$1,167,375,660	5 / 5
2026-10-10	$2.00	$1,167,375,660	5 / 5
2026-10-11	$2.00	$1,167,375,660	5 / 5
2026-10-12	$2.00	$1,167,375,660	5 / 5
2026-10-13	$2.00	$1,167,375,660	5 / 5
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	10	1
2026-06-01	8	10	1
2026-07-01	8	10	2
2026-08-01	8	10	2
2026-09-01	8	10	2
2026-10-01	9	10	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 10 Hold · 2 Sell / Strong Sell

1 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wells FargoOct 19

$46.00New observation · no comparable prior

BarclaysOct 13 · prior Aug 31

$50.00 → $48.00-4.0%

Raymond JamesOct 6 · prior Jun 16

$50.00 → $53.00+6.0%

$0$29.15$58.30

1 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain dividend per share at $0.67Dividend per share: $0.67 per share
Achieve EPS near $3.22 for FY 2026Diluted EPS: $1.19 per share
Net income improves to positive $151 million quarterlyNet income: $362.823M
Increase revenue to at least $323 million quarterlyRevenue: $328.246M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.7%Typical daily move · historical

Downside history

-15.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Omega Healthcare Investors outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

OHI is a healthcare real estate investment trust with a dividend and growth thesis tied to investing in properties and loans. The thesis is intact: recent financial performance is strong, and company quality and management assessments have improved, though management is rated neutral overall.

What's priced into Omega Healthcare Investors

The valuation evidence is mixed: OHI is assessed as cheap, but it carries a 2.0% premium versus peers, and model confidence is low. The expectations gap is 0.39, while the priced-in tag is marked unjustified; the evidence does not explain that tag further.

What the fundamentals likely do

Near term, recent results and continued investment deployment support the business: management raised 2026 AFFO guidance, or adjusted funds from operations per share, and increased the quarterly dividend slightly. The sector backdrop is a headwind, and the recent guidance increase makes any reversal a credibility risk; the evidence also notes a high-miss-rate industry and a deep miss in OHI’s recent history.

What Omega Healthcare Investors hinges on

Over the next 1 to 3 years, the thesis depends on management sustaining investment returns and executing without cutting recently raised guidance. Lower interest rates and continued strong results from sector peers could support the sector backdrop, while a guidance reversal would weaken confidence.